Table 1.
Patient characteristics (n=349).
| Conventional RT (n=126) | Hypofractionated RT (n=223) | P-value | |
|---|---|---|---|
| Age (year) | |||
| < 45 | 69 (54.8%) | 122 (54.7%) | 0.992 |
| ≥ 45 | 57 (45.2%) | 101 (45.3%) | |
| Body mass index | |||
| <23 | 67 (53.2%) | 117 (52.5%) | 0.899 |
| ≥23 | 59 (46.8%) | 106 (47.5%) | |
| Laterality | |||
| Left | 62 (49.2%) | 114 (48.5%) | 0.753 |
| Right | 64 (50.8%) | 120 (51.1%) | |
| Bilateral | 0 (0.0%) | 1 (0.4%) | |
| Histology | |||
| IDC | 107 (84.9%) | 195 (87.4%) | 0.524 |
| Others+ | 19 (15.1%) | 29 (12.6%) | |
| Molecular type | |||
| Luminal A | 58 (46.1%) | 118 (52.9%) | 0.038 |
| Luminal B | 41 (32.5%) | 53 (23.7%) | |
| Her-2 enriched | 9 (7.1%) | 28 (12.6%) | |
| TNBC | 14 (11.1%) | 23 (10.3%) | |
| None | 4 (3.2%) | 1 (0.5%) | |
| Neoadjuvant chemotherapy | |||
| Yes | 40 (31.8%) | 100 (44.8%) | 0.017 |
| No | 86 (68.2%) | 123 (55.2%) | |
| Adjuvant chemotherapy | |||
| Yes | 69 (55.2%) | 102 (45.7%) | 0.090 |
| No | 56 (44.8%) | 121 (54.3%) | |
| Anti Her-2 therapy | |||
| Yes | 23 (18.3%) | 49 (22.0%) | 0.410 |
| No | 103 (81.7%) | 174 (78.0%) | |
| Endocrine therapy | |||
| Tamoxifen | 74 (58.7%) | 129 (57.9%) | 0.044 |
| Tamoxifen+zoladex | 9 (7.1%) | 31 (13.9%) | |
| Aromatase inhibitor | 13 (10.3%) | 31 (13.9%) | |
| No | 30 (23.8%) | 32 (14.3%) | |
| Operation type | |||
| Mastectomy | 91 (72.2%) | 176 (78.9%) | 0.156 |
| BCS | 35 (27.8%) | 47 (21.1%) | |
| Lymph node staging | |||
| SLNB | 44 (34.9%) | 101 (45.3%) | 0.082 |
| ALND | 80 (63.5%) | 122 (54.7%) | |
| None | 2 (1.6%) | 0 (0.0%) | |
| Reconstruction type | |||
| LD flap | 37 (29.4%) | 53 (23.8%) | <0.001 |
| TRAM | 69 (54.8%) | 68 (30.5%) | |
| Implant | 19 (15.1%) | 101 (45.3%) | |
| Others* | 1 (0.7%) | 1 (0.4%) | |
| RT technique | |||
| 3D | 119 (94.4%) | 79 (35.4%) | <0.001 |
| IMRT | 7 (5.6%) | 144 (64.6%) | |
| RT to SCL | |||
| Yes | 83 (65.9%) | 159 (71.3%) | 0.263 |
| No | 43 (34.1%) | 64 (28.7%) | |
| RT to IMN | |||
| Yes | 6 (4.8%) | 112 (50.2%) | <0.001 |
| No | 120 (95.2%) | 111 (49.8%) | |
| Tumor bed boost | |||
| Yes | 47 (37.3%) | 60 (26.9%) | 0.043 |
| No | 79 (62.7%) | 163 (73.1%) | |
| Bolus | |||
| Yes | 36 (28.6%) | 36 (16.1%) | 0.006 |
| No | 80 (71.4%) | 83 (83.9%) | |
P-value by chi-square test.
Others+, intralobular carcinoma, mucinous carcinoma, phyllodes tumor, invasive mammary carcinoma
Abbreviations: IDC, intraductal carcinoma; TNBC, triple negative breast cancer; BCS, breast-conserving surgery; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; LD flap. latissimus dorsi flap; TRAM, transverse rectus abdominis myocutaneous flap; 3D, 3-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; SCL, supraclavicular lymph node; IMN, internal mammary lymph node Others*, fat graft, advancement flap, free deep inferior epigastric artery perforator.